Literature DB >> 19221540

Dress syndrome and fulminant hepatic failure induced by lamotrigine.

Marcelo Fabián Amante1, Analía Verónica Filippini, Nora Cejas, Javier Lendoire, Oscar Imventarza, Coloma Parisi.   

Abstract

Lamotrigine is a non-aromatic antiepileptic drug. Drug rash with eosinophilia and systemic symptoms (DRESS) syndrome is a severe idiosyncratic reaction to drugs, especially anti-epileptic drugs. Associated clinical features include cutaneous eruption, fever, multiple peripheral lymphadenopathies, and potentially life-threatening damage of one or more organs. We report a case of DRESS syndrome induced by lamotrigine presenting with a hypersensitivity syndrome and fulminant hepatic failure requiring liver transplant. A 21-year old female patient presented an episode of seizure with loss of conscience. CT and EEG studies performed were normal. Treatment with lamotrigine was prescribed. In the course of 30 days, the patient developed skin lesions, pruritus, cholestatic hepatitis, and systemic symptoms -fever, lymphadenopathies, extensive exfoliative erythematous maculopapular rash, and jaundice. Serologic and laboratory tests showed no other causes responsible for the clinical spectrum. Hematologic tests revealed peripheral eosinophilia. Fulminant hepatic failure was diagnosed and an orthotopic liver transplant was performed. Histologic sections of the explanted liver demonstrated submassive hepatic necrosis, with the remnant portal spaces and lobules showing a mixed inflammatory infiltrate with lymphocytes and eosinophils. Lamotrigine treatment has been associated with multiorgan failure, DRESS syndrome, acute hepatic failure, and disseminated intravascular coagulation. In conclusion, we suggest that these potentially fatal side effects should be considered in any patient with clinical deterioration following administration of this drug.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19221540

Source DB:  PubMed          Journal:  Ann Hepatol        ISSN: 1665-2681            Impact factor:   2.400


  8 in total

1.  Multidrug-related leukocytoclastic vasculitis raising suspicion of sexual homicide-things are not always what they seem.

Authors:  Lucia Tattoli; Klaus Krocker; Julia Sautter; Michael Tsokos
Journal:  Int J Legal Med       Date:  2015-05-10       Impact factor: 2.686

2.  Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS) in an Adolescent Treated With Lamotrigine.

Authors:  Almari Ginory; Michelle Chaney-Catchpole; Julie M Demetree; Laura M Mayol Sabatier; Mathew Nguyen
Journal:  J Pediatr Pharmacol Ther       Date:  2013-07

3.  Seizure management in the setting of hepatic disease.

Authors:  Jane G Boggs
Journal:  Curr Treat Options Neurol       Date:  2011-08       Impact factor: 3.598

Review 4.  Controversies in Allergy: The Potential Role of Biologics as First-Line Therapy in Eosinophilic Disorders.

Authors:  Evan S Dellon; Dagmar Simon; Michael E Wechsler
Journal:  J Allergy Clin Immunol Pract       Date:  2022-02-12

Review 5.  Recent advances of pharmacogenomics in severe cutaneous adverse reactions: immune and nonimmune mechanisms.

Authors:  Ro-Lan Dao; Shih-Chi Su; Wen-Hung Chung
Journal:  Asia Pac Allergy       Date:  2015-04-29

Review 6.  An Updated Review of Genetic Associations With Severe Adverse Drug Reactions: Translation and Implementation of Pharmacogenomic Testing in Clinical Practice.

Authors:  Chuang-Wei Wang; Ivan Arni C Preclaro; Wei-Hsiang Lin; Wen-Hung Chung
Journal:  Front Pharmacol       Date:  2022-04-25       Impact factor: 5.988

7.  Lamotrigine induced DRESS syndrome.

Authors:  Kikkeri Narayanasetty Naveen; Mysore Satyanarayana Ravindra; Varadraj V Pai; Vijetha Rai; Sharatchandra B Athanikar; Meravanige Girish
Journal:  Indian J Pharmacol       Date:  2012 Nov-Dec       Impact factor: 1.200

Review 8.  Current Perspectives on Severe Drug Eruption.

Authors:  Jingzhan Zhang; Zixian Lei; Chen Xu; Juan Zhao; Xiaojing Kang
Journal:  Clin Rev Allergy Immunol       Date:  2021-07-17       Impact factor: 8.667

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.